|

Adagrasib Clinical Trials

8 actively recruiting trials across 6 locations

▲ +1 trial since June 2026

Also known as: BMS-986503, BMS-986503; KRAZATI®, KRAS G12C Inhibitor MRTX849, KRAZATI, Krazati +5 more

Pipeline

Phase 1: 2Phase 2: 3Phase 3: 1Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Mirati Therapeutics Inc.3
  • Ryan Gentzler, MD1
  • M.D. Anderson Cancer Center1
  • Kura Oncology, Inc.1
  • City of Hope Medical Center1

Indications

  • Cancer8
  • Lung Cancer6
  • Solid Tumors With HRAS Alterations1
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)1
  • KRAS G12C1

Goodyear, Arizona2 trials

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-556-A

Phase 2/3

Phoenix, Arizona2 trials

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Local Institution - 0005

Phase 2
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1

Birmingham, Alabama1 trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3

Boston, Massachusetts1 trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2

Hackensack, New Jersey1 trial

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1

Columbus, Ohio1 trial

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.